» Articles » PMID: 16469876

Molecular Dissection of Meis1 Reveals 2 Domains Required for Leukemia Induction and a Key Role for Hoxa Gene Activation

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2006 Feb 14
PMID 16469876
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The Hoxa9 and Meis1 genes represent important oncogenic collaborators activated in a significant proportion of human leukemias with genetic alterations in the MLL gene. In this study, we show that the transforming property of Meis1 is modulated by 3 conserved domains, namely the Pbx interaction motif (PIM), the homeodomain, and the C-terminal region recently described to possess transactivating properties. Meis1 and Pbx1 interaction domain-swapping mutants are dysfunctional separately, but restore the full oncogenic activity of Meis1 when cotransduced in primary cells engineered to overexpress Hoxa9, thus implying a modular nature for PIM in Meis1-accelerated transformation. Moreover, we show that the transactivating domain of VP16 can restore, and even enhance, the oncogenic potential of the Meis1 mutant lacking the C-terminal 49 amino acids. In contrast to Meis1, the fusion VP16-Meis1 is spontaneously oncogenic, and all leukemias harbor genetic activation of endogenous Hoxa9 and/or Hoxa7, suggesting that Hoxa gene activation represents a key event required for the oncogenic activity of VP16-Meis1.

Citing Articles

Ubiquitous MEIS transcription factors actuate lineage-specific transcription to establish cell fate.

Darieva Z, Zarrineh P, Phillips N, Mallen J, Garcia Mora A, Donaldson I EMBO J. 2025; .

PMID: 40021842 DOI: 10.1038/s44318-025-00385-5.


Normal and Aberrant TALE-Class Homeobox Gene Activities in Pro-B-Cells and B-Cell Precursor Acute Lymphoblastic Leukemia.

Nagel S, Meyer C Int J Mol Sci. 2022; 23(19).

PMID: 36233173 PMC: 9570312. DOI: 10.3390/ijms231911874.


MEIS1 in Hematopoiesis and Cancer. How MEIS1-PBX Interaction Can Be Used in Therapy.

Blasi F, Bruckmann C J Dev Biol. 2021; 9(4).

PMID: 34698191 PMC: 8544432. DOI: 10.3390/jdb9040044.


MEIS1 and its potential as a cancer therapeutic target (Review).

Yao M, Gu Y, Yang Z, Zhong K, Chen Z Int J Mol Med. 2021; 48(3).

PMID: 34318904 PMC: 8354308. DOI: 10.3892/ijmm.2021.5014.


Mapping the native interaction surfaces of PREP1 with PBX1 by cross-linking mass-spectrometry and mutagenesis.

Bruckmann C, Tamburri S, De Lorenzi V, Doti N, Monti A, Mathiasen L Sci Rep. 2020; 10(1):16809.

PMID: 33033354 PMC: 7545097. DOI: 10.1038/s41598-020-74032-w.